Antibody Information
General Information of This Antibody
| Antibody ID | ANI0ZCCGC |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | 3ee9 |
|||||
| Antigen Name | Carbonic anhydrase 9 (CA9) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
BAY79-4620 [Phase 1 (Terminated)]
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT01065623 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open label phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY79-4620 administered as an intravenous infusion once every 2 weeks in patients with advanced solid tumors.
|
||||
| Experiment 2 Reporting the Activity Date of This ADC | [2] | ||||
| Related Clinical Trial | |||||
| NCT Number | NCT01028755 | Clinical Status | Phase 1 | ||
| Clinical Description |
An open label phase 1 study to evaluate the safety, tolerability, pharmacokinetics and maximum tolerated dose of BAY79-4620 in patients with advanced solid tumors.
|
||||
References